Streptomyces peucetius
S. peucetius produces the anthracycline antitumor antibiotics daunorubicin and doxorubicin (also known as adriamycin). Recent ...
FCM (chemotherapy)
... a synthetic anthracycline analogue (anthraquinone) that can intercalate DNA, thereby preventing cell division. The addition of ...
Cysteine dioxygenase
... inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines". ...
Pharmacological cardiotoxicity
From early observations, some of the first ones which go under the name of anthracycline. It has emerged that such drugs cause ...
ATP-binding cassette transporter
ABCG2 can export anthracycline anticancer drugs, as well as topotecan, mitoxantrone, or doxorubicin as substrates. Chromosomal ... and the anthracycline modified drugs (annamycin and doxorubicin-peptide). These drugs would not function as a substrate of ABC ...
Pegaspargase
Often it is used together with anthracycline, vincristine, and corticosteroids (for example prednisone and dexamethasone). ...
Cardiovascular Cell Therapy Research Network
In September 2016, CCTRN opened enrollment in a study in anthracycline-induced cardiomyopathy (AIC): SENECA (NCT02509156). The ... Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. ...
Free radical damage to DNA
"DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores". ...
CytRx
Doxorubicin, the first anthracycline to gain approval, has demonstrated efficacy in a wide variety of cancers including breast ... Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as ... "red death". Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. ...
Immunogenic cell death
ICD is induced by some cytostatic agents such as anthracyclines, oxaliplatin and bortezomib, or radiotherapy and photodynamic ...
Phenformin
"In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell ...
Tumor hypoxia
Almoustafa, Hassan A.; Alshawsh, Mohammed A.; Chik, Zamri (March 2021). "Targeted polymeric nanoparticle for anthracycline ...
Polymer-drug conjugates
... shows up to a 5 times reduction in anthracycline type toxicity compared to current treatments. Doses up to 1680 mg/m2 observed ...
Acute promyelocytic leukemia
It produces less cardiotoxicity than anthracycline-based treatments and hence may be preferable in these patients. After stable ... which is comparable to the rate seen in patients treated with ATRA and anthracycline-based therapy. ... before 2013 the standard of treatment was anthracycline (e.g. daunorubicin, doxorubicin, idarubicin or mitoxantrone)-based ... gene fusion produces a subtype of APL that is unresponsive to tretinoin therapy and less responsive to standard anthracycline ...
Daunosamine
... is a component of the anthracycline class of antineoplastics, linked to a derivative of naphthacene. It is a ...
Hypothermia cap
... specifically when taxanes or anthracyclines are used. It should not be used when cancer is present in the skin of the scalp or ...
Aclarubicin
... (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer. Soil bacteria ... Anthracyclines, Topoisomerase inhibitors, All stub articles, Antineoplastic and immunomodulating drug stubs). ...
Monomorphic epitheliotropic intestinal T cell lymphoma
Most individuals have been treated by surgical resections of involved areas with or without anthracycline-based chemotherapy. ...
FM (chemotherapy)
... a synthetic anthracycline analogue (an anthraquinone) that is able to intercalate DNA and prevent mitosis. This regimen is also ...
ANKRD1
In cardiomyocytes treated with doxorubicin, a model of anthracycline-induced cardiomyopathy, CARP mRNA and protein levels were ... implications for anthracycline cardiomyopathy". PLOS ONE. 7 (4): e35743. Bibcode:2012PLoSO...735743C. doi:10.1371/journal.pone. ...
Troponin
Chemotherapy agents can exert toxic effects on the heart (examples include anthracycline, cyclophosphamide, 5-fluorouracil, and ...
Trivial name
In 1977 the components were isolated and have been found useful as antitumor agents and anthracycline antibiotics. The authors ...
Prophylactic cranial irradiation
Jun 1, 2000). "Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial ...
Hair loss
... when taxanes or anthracyclines are administered. It is not recommended to be used when cancer is present in the skin of the ...
MINE (chemotherapy)
... a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis); ...
FLAG (chemotherapy)
In the FLAG-IDA regimen (also called FLAG-Ida, IDA-FLAG, or Ida-FLAG), idarubicin-an anthracycline antibiotic that is able to ... Mitoxantrone is a synthetic anthracycline analogue (an anthracenedione) that, like idarubicin, can intercalate DNA and prevent ...
Germinal center B-cell like diffuse large B-cell lymphoma
"14-3-3ΞΆ Mediates Resistance of Diffuse Large B Cell Lymphoma to an Anthracycline-based Chemotherapeutic Regimen". Journal of ...
Kurt Hellmann
In 1996, he predicted the importance of preventing pharmacological anthracycline cardiotoxicity in quality of life of cancer ...
Valrubicin
... is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the ... Anthracyclines, Topoisomerase inhibitors, Trifluoromethyl compounds, Acetamides, Withdrawn drugs). ...
Eribulin
Prior therapy should have included an anthracycline and a taxane unless the people were not suitable for these treatments. ... adults with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced ... including both anthracycline- and taxane-based chemotherapies. It was approved by Health Canada on December 14, 2011, with an ... MBC Previously Treated With Anthracyclines & Taxanes (KELLY)" at ClinicalTrials.gov "Patent and Exclusivity for: N201532". ...